XML 22 R10.htm IDEA: XBRL DOCUMENT v3.25.1
Revenue
 6 Months Ended
Mar. 31, 2025
Revenue from Contract with Customer [Abstract]  
Revenue Revenue
The Company’s revenue is generated through the sale of synthetic biology tools, such as synthetic genes, oligo pools, NGS tools, DNA libraries and biopharma services for antibody discovery, optimization and development ("Biopharma").
Contract Balances
The following table summarizes our contract balances:
(in thousands) March 31,
2025		September 30,
2024
Contract assets(1)
$1,475 $2,031 
Contract liabilities(2)
1,988 2,131 
(1) Consists of unbilled amounts primarily related to Biopharma contracts which consists of research and development agreements with third parties.
(2) Consists of receipt of advance payment before our performance obligations related to Biopharma contracts are met.
For the three and six months ended March 31, 2025, the Company recognized revenue of $0.6 million and $1.4 million, respectively, from the amount that was included in the contract liability balance at the beginning of each period. For the three and six months ended March 31, 2024, the Company recognized revenue of $0.9 million and $2.2 million, respectively, from the amount that was included in the contract liability balance at the beginning of each period.
In addition, for all periods presented, there was no revenue recognized in a reporting period from performance obligations satisfied in previous periods. The aggregate amount of the transaction price allocated to the performance obligations that are unsatisfied as of March 31, 2025 was $8.5 million. The Company expects to recognize revenue over the next twelve months relating to performance obligations unsatisfied as of March 31, 2025.
Based on the nature of the Company’s contracts with customers which are recognized over a term of less than 12 months, the Company has elected to use the practical expedient whereby costs to obtain a contract are expensed as they are incurred. The Company states its revenues net of any taxes collected from customers that are required to be remitted to various government agencies. The amount of taxes collected from customers and payable to governmental entities is included on the balance sheet as part of “Accrued expenses and other current liabilities.”
Disaggregation of Revenues

The table below sets forth revenues by geographic region, based on ship-to destinations. Americas consists of the United States, Canada, Mexico and South America; EMEA consists of Europe, the Middle East, and Africa; and APAC consists of Japan, China, South Korea, India, Singapore, Malaysia and Australia.

Three Months Ended
March 31,		Six Months Ended
March 31,
(in thousands)2025202420252024
Americas$55,189 $45,873 $108,899 $89,832 
EMEA30,64222,26358,94543,483
APAC6,9627,16613,66213,485
Total$92,793 $75,302 $181,506 $146,800 
The table below sets forth revenues by products.
Three Months Ended
March 31,		Six Months Ended
March 31,
(in thousands)2025202420252024
Synthetic genes$28,222 $22,356 $54,708 $42,083 
Oligo pools4,7113,9409,8048,129
DNA libraries3,0173,5315,8116,470
Antibody discovery5,6974,70111,3959,927
NGS tools51,14640,77499,78880,191
Total$92,793 $75,302 $181,506 $146,800 

The table below sets forth revenues by industry.

Three Months Ended
March 31,		Six Months Ended
March 31,
(in thousands)2025202420252024
Industrial chemicals/materials$22,795 $20,264 $43,998 $36,542 
Academic research16,52713,72234,07327,495
Healthcare52,76640,934102,13581,815
Food/agricultural7053821,300948
Total$92,793 $75,302 $181,506 $146,800